48 results
8-K
EX-99.1
NUVL
Nuvalent Inc - Ordinary Shares
9 May 24
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial Results
6:37am
of adverse safety events; risks that the FDA may not approve our potential products on the timelines we expect, or at all; risks of unexpected costs
8-K
EX-99.1
NUVL
Nuvalent Inc - Ordinary Shares
27 Feb 24
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial Results
6:38am
clinical trial is designed to evaluate the safety and activity of NVL-655 in several expansion cohorts of patients defined based on the number and type … not achieve the goals and milestones set forth in its OnTarget 2026 operating plan; the occurrence of adverse safety events; risks that the FDA may not approve
8-K
EX-99.1
NUVL
Nuvalent Inc - Ordinary Shares
9 Jan 24
Nuvalent Announces “OnTarget 2026” Operating Plan and Key Anticipated Milestones
4:40pm
of adverse safety events; risks that the FDA may not approve our potential products on the timelines we expect, or at all; risks of unexpected costs
8-K
EX-99.1
tcu7viml0pymtfzz
14 Nov 23
Nuvalent Highlights Corporate and Pipeline Achievements and Reports Third Quarter
6:45am
8-K
EX-1.1
l47 th1ual85puf0dp
17 Oct 23
Nuvalent Announces Pricing of Public Offering of Common Stock
4:07pm
424B5
bl6s6nrul bunxzf7
17 Oct 23
Prospectus supplement for primary offering
4:05pm
424B5
6s0jo6z8t8tu0fp6wqf5
16 Oct 23
Prospectus supplement for primary offering
7:39am
8-K
sb1ym43 y2wmwg84w
13 Oct 23
Nuvalent Reports Preliminary Phase 1 Clinical Data from ALKOVE-1 Trial
6:40am
8-K
EX-99.1
2tq2tp3a
13 Oct 23
Nuvalent Reports Preliminary Phase 1 Clinical Data from ALKOVE-1 Trial
6:40am
8-K
EX-99.1
zt1gcnc3zp6
4 Oct 23
Other Events
4:05pm
8-K
el6wl bh4d
4 Oct 23
Other Events
4:05pm
8-K
EX-99.1
d5o vni6c
10 Aug 23
Nuvalent Highlights Pipeline Progress and Reports Second Quarter 2023 Financial Results
6:45am
8-K
EX-99.1
75qy2qh2fi0lu1gt
11 May 23
Nuvalent Announces Anticipated Timing of Preliminary Phase 1 Dose-Escalation Data for NVL-655 and Reports First Quarter 2023 Financial Results
6:39am
8-K
EX-99.1
nn60fynmddwh5ke
10 Nov 22
Nuvalent Reviews Corporate and Pipeline Achievements and Reports Third Quarter 2022 Financial Results
6:37am